Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokine in COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable COPD without an exacerbation within 3 months prior to study entry~* mild, moderate and severe COPD with or without treatments, regardless of COPD medications~Exclusion Criteria:~* Concomitant other chronic lung diseases including with TB and malignancy~* HIV~* Being on immunosuppressive drugs and systemic corticosteroids~* Dyslipidemic patients with recent cardiovascular or cerebrovascular disease within 6 month prior to study entry~* Cognitive impairment~* Currently on macrolides, azole anti-fungal agents, amiodarone and amlodipine

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Simvastatin (Type: EXPERIMENTAL): simvastatin 20 mg/d is randomized to treat COPD patients for 4 weeks
- B1-6-12 (Type: PLACEBO_COMPARATOR): B1-6-12 one tablet a day is randomized to give to COPD patients for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).